IL1B and myocardial infarction: Importantly, the IL-1β-neutralizing antibody canakinumab has demonstrated considerable clinical benefits, reducing recurrent cardiovascular events by 17% in patients with a previous myocardial infarction (CANTOS trial), independent of the lipid level [119].